Announced Tue, 24 Mar · 16:43 IST
DISCLOSURE UNDER REGULATION 7(2) OF SEBI (PROHIBITION OF INSIDER TRADING) REGULATIONS, 2015
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-12.4%1-day move
₹21.00
prior close
—
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————-12.4-8.2-9.6-10.2-10.2+19.0+17.6+4.8-9.5+11.9
Up moveDown movePending
AI summary
Beryl Drugs Ltd has submitted a disclosure under SEBI Insider Trading Regulations regarding an acquisition by its main Promoter and Director, Sudhir Sethi (DIN: 00090172). He purchased 7,500 shares, representing 0.14% of the company's total share capital. The disclosure was filed with BSE on March 24, 2026, as required under Regulation 7(2). The transaction size is small in proportion to overall holdings.
Likely market impact
This is a minor insider buy that signals promoter confidence, but the 0.14% stake addition is too small to materially affect shareholding structure or stock price.